Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
0.0010
0.0000
(0.00%)
At close: February 27 at 3:00:00 PM EST
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Operating Expense
21,019.7760
21,019.7760
29,487.1990
17,189.6990
15,691.0170
Operating Income
-21,019.7760
-21,019.7760
-29,487.1990
-17,189.6990
-15,691.0170
Net Non Operating Interest Income Expense
-210.4960
-210.4960
-746.2800
-627.1500
-3.2310
Other Income Expense
8,710.1000
8,710.1000
4,825.9150
2,082.1690
-263.7900
Pretax Income
-12,520.1720
-12,520.1720
-25,407.5640
-15,734.6800
-15,113.7110
Tax Provision
9.6770
9.6770
92.8200
163.7200
--
Net Income Common Stockholders
-12,529.8490
-12,529.8490
-25,500.3840
-15,898.4000
-15,113.7110
Basic EPS
-0.02
-0.02
-0.06
-0.04
-0.08
Diluted EPS
-0.02
-0.02
-0.06
-0.04
-0.08
Basic Average Shares
695,639.5240
695,639.5240
433,244.5400
359,932.4420
188,716.7060
Diluted Average Shares
695,639.5240
695,639.5240
433,244.5400
359,932.4420
188,716.7060
Net Income from Continuing & Discontinued Operation
-12,529.8490
-12,529.8490
-25,500.3840
-15,898.4000
-15,113.7110
Normalized Income
-12,529.1532
-12,529.1532
-25,498.6704
-15,896.9545
-15,113.7110
Interest Income
121.3150
121.3150
27.5650
12.9770
2.6460
Interest Expense
331.8110
331.8110
773.8450
640.1270
5.8770
Net Interest Income
-210.4960
-210.4960
-746.2800
-627.1500
-3.2310
EBIT
-12,188.3610
-12,188.3610
-24,633.7190
-15,094.5530
-15,107.8340
EBITDA
-11,182.2320
-11,182.2320
-23,668.3680
-14,144.7910
-14,260.8740
Reconciled Depreciation
1,006.1290
1,006.1290
965.3510
949.7620
846.9600
Net Income from Continuing Operation Net Minority Interest
-12,529.8490
-12,529.8490
-25,500.3840
-15,898.4000
-15,113.7110
Total Unusual Items Excluding Goodwill
-0.9940
-0.9940
-2.4480
-2.0650
--
Total Unusual Items
-0.9940
-0.9940
-2.4480
-2.0650
--
Normalized EBITDA
-11,181.2380
-11,181.2380
-23,665.9200
-14,142.7260
-14,260.8740
Tax Rate for Calcs
0.0003
0.0003
0.0003
0.0003
--
Tax Effect of Unusual Items
-0.2982
-0.2982
-0.7344
-0.6195
--
6/30/2021 - 11/30/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RAD.AX Radiopharm Theranostics Limited
0.0260
0.00%
IUGNF Imugene Limited
0.0270
+4.25%
IMU.AX Imugene Limited
0.0370
-2.63%
RADX Radiopharm Theranostics Limited
5.0000
-5.84%
VALN Valneva SE
6.75
-5.20%
CELU Celularity Inc.
1.1600
-4.92%
NRXP NRx Pharmaceuticals, Inc.
2.2700
-0.87%
MESO Mesoblast Limited
17.15
+10.36%
CAPR Capricor Therapeutics, Inc.
15.38
+6.95%
IOVA Iovance Biotherapeutics, Inc.
4.2350
-19.49%